About Dr. Bhawna Sirohi
Dr. Bhawna Sirohi is a globally recognized medical oncologist with expertise in treating gastrointestinal and breast cancers. Trained in both India and the UK, she is known for her evidence-based, patient-focused approach, emphasizing early diagnosis, survivorship, and access to quality care. Dr. Sirohi has held leadership roles at top oncology centers and actively contributes to global oncology standards through organizations like Lancet Oncology and ASCO. Her areas of focus include chemotherapy, immunotherapy, and targeted therapy. Widely respected for her compassionate care, she is also an advocate for health equity and innovation in cancer management.
- MBBS – LLRM Medical College, Meerut, India
- DCH (Diploma in Child Health) – LLRM Medical College, Meerut, India
- Medical Oncology Training – Tata Memorial Centre, Mumbai, India
- Specialist Training (CCT) in Medical Oncology – UK
- Fellowship – Royal College of Physicians (FRCP), London
- Breast Cancer
- Colorectal Cancer
- Pancreatic and Gallbladder Cancer
- Neuroendocrine Tumors
- Stomach Cancer
- Liver (Hepatocellular) Cancer
- Personalised Cancer Therapy
- Cancer Survivorship Programs
- Early Detection and Cancer Prevention
- Global Oncology and Health Equity Initiatives
- Gastrointestinal Oncology
- Breast Oncology
- Advanced Chemotherapy Protocols
- Hormonal Therapy
- Targeted Therapy
- Immunotherapy Approaches
- Survivorship Planning and Financial Counseling
- Medical Director & Senior Medical Oncologist, BALCO Medical Centre, Raipur (Current)
- Lead Medical Oncologist, Apollo Proton Cancer Centre, Chennai
- Director of Medical Oncology, Max Cancer Centre, New Delhi
- Head of Medical Oncology, Artemis Cancer Centre, Gurgaon
- Consultant Medical Oncologist, Tata Memorial Centre, Mumbai
- Consultant Oncologist, Royal Marsden NHS Foundation Trust, London
- Consultant, Addenbrookes NHS Trust and Barts Health NHS Trust, UK
- President, Oncology Section, Royal Society of Medicine, UK (2018–2019)
- Honorary Consultant, Queen Mary University, London (2018–2021)
- Member, Lancet Oncology International Advisory Board
- Founder President, New India Cancer Charity Initiative (NICCI)
- Contributing member of ASCO Committees on health equity, climate change, and outcomes research
- Anu, R. I., Patel, A., Pathak, N., Mehta, P., Chougule, A., Sheth, H., … & Kulkarni, P. (2025). Uniform Reporting of Next Generation Sequencing: Indian Society of Medical and Pediatric Oncology. Indian Journal of Medical and Paediatric Oncology.
- Varshney, P., Baghmar, S., Sirohi, B., Abou-Alfa, G. K., Cao, H. T., Sharma, L. M., … & Kapoor, V. K. (2025). Neoadjuvant treatment for incidental gallbladder cancer: A systematic review. Annals of Hepato-Biliary-Pancreatic Surgery, 29(2), 113.
- Bajpai, J., Gandhi, S. S., Rajappa, S., Pathak, R., Joshi, S., Batra, A., … & Aggrawal, S. (2024). Indian Society of Medical and Paediatric Oncology (ISMPO)—Breast Cancer in Young Guidelines. Indian Journal of Medical and Paediatric Oncology.
- Palepu, J., Endo, I., Chaudhari, V. A., Murthy, G. V. S., Chaudhuri, S., Adam, R., … & Jarnagin, W. (2024). ‘IHPBA-APHPBA clinical practice guidelines’: international Delphi consensus recommendations for gallbladder cancer. HPB, 26(11), 1311-1326.
- Language Support
- Visa & Travel Assistance
- Pre-treatment Virtual Consultations
Treatment Type | Estimated Cost (INR) | Estimated Cost (USD) |
Chemotherapy Cycle | ₹30,000 – ₹80,000 | $400 – $1,100 |
Targeted Therapy | ₹1,00,000 – ₹3,00,000 | $1,300 – $4,000 |
Immunotherapy Cycle | ₹1,50,000 – ₹4,00,000 | $2,000 – $5,300 |
Hormonal Therapy | ₹20,000 – ₹50,000 | $260 – $660 |